DS-2243 / Daiichi Sankyo - LARVOL DELTA

DS-2243a, an HLA-A*02/NY-ESO-directed bispecific T‑cell engager, shows potent anti-tumor activity in preclinical models of solid tumors (AACR 2026) - P1 | "Preclinical data indicate that DS-2243a has strong potential to deliver clinically meaningful anti-tumor activity in patients with HLA-A*02 and NY-ESO-expressing cancers. The first-in-human study DS2243-054 (NCT06644755) is being conducted to evaluate DS-2243a monotherapy in patients with advanced or metastatic solid tumors."

Bispecific • First-in-human • IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CTAG1B • CTAG2 • HLA-A

A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors. (ASCO 2025) - P1 | "Secondary outcome measures include ORR (dose escalation only), time to response, duration of response, progression-free survival (all assessed by the investigator per RECIST 1.1), and overall survival. The planned sample size is ~150 patients; enrollment is ongoing."

Clinical • Metastases • P1 data • Liposarcoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Synovial Sarcoma • Urothelial Cancer • CTAG1B • CTAG2 • HLA-A

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer